Engineered immune cells take on tough blood cancers in new trial
NCT ID NCT07502118
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The trial will enroll 40 adults and monitor them for about 30 months to see how well the treatment works and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Talikabtagene Autoleucel (a personalized cell therapy made from the patient's own immune cells, engineered to attack cancer)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat blood cancers, potentially leading to long-term remission.
- What could go wrong
- This is an early-to-mid-stage trial with only 40 participants. The therapy may cause serious side effects like cytokine release syndrome or neurotoxicity, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ankara Bilkent City Hospital - Hematology Clinic
RECRUITINGAnkara, Turkey (Türkiye)
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ankara Etlik City Hospital - Hematology Clinic
RECRUITINGAnkara, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hacettepe University Faculty of Medicine - Department of Internal Medicine, Division of Hematology
NOT_YET_RECRUITINGAnkara, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
RECRUITINGAnkara, Turkey (Türkiye)
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Can a Three-Drug cocktail replace chemo for follicular lymphoma?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New drug combo aims to boost lymphoma treatment